Table 4.
Comparison COVID-19 on ECMO and Non-COVID-19 on ECMO.
| COVID-19 (n = 71) |
Non-COVID ARDS (n = 48) |
P value | ||||
|---|---|---|---|---|---|---|
| Pre-ECMO patient characteristics | ||||||
| Age, median (IQR), years | 52 | (47-57) | 55 | (40-61) | .49 | |
| Male gender, No (%) | 57 | (80) | 24 | (50) | .001 | |
| Body mass index, median (IQR), kg/m2 | 29.2 | (26.1-32.1) | 28.3 | (24.7-33) | .84 | |
| SOFA-score, median (IQR) | 9 | (7-12) | 10 | (9-13) | .13 | |
| PaO2/FiO2-ratio, median (IQR), mmHg | 58 | (46-76) | 53 | (44-67) | .84 | |
| Lactate, median (IQR), mmol/L | 1.7 | (1.2-2.8) | 1.4 | (1.1-2.7) | .27 | |
| Medical history, No. (%) | ||||||
| Hypertension | 15 | (21) | 13 | (27) | >.99 | |
| Diabetes | 6 | (8%) | 4 | (8%) | >.99 | |
| Asthma | 7 | (10) | 3 | (6) | .63 | |
| COPD | 4 | (6) | 1 | (2) | .60 | |
| ECMO characteristics and complications | ||||||
| Complications, No. (%) | ||||||
| Hemorrhage | 38 | (54) | 22 | (46) | .53 | |
| Arterial thrombosis | 3 | (4) | 0 | (0) | .27 | |
| Venous thrombosis | 8 | (11) | 4 | (8) | .76 | |
| Mechanic thrombosis | 10 | (14) | 7 | (15) | >.99 | |
| Infection | 40 | (56) | 26 | (54) | .96 | |
| Acute kidney injury | 39 | (55) | 27 | (56) | >.99 | |
| ECMO run duration, median, d | 13 | (7-20) | 9 | (5-17) | .16 | |
| 28-day mortalitya, No. (%) | 26 | (37) | 19 | (27) | .49 | |
Abbreviations: COPD, chronic obstructive pulmonary disease; SOFA, sequential organ failure assessment; COPD, chronic obstructive pulmonary disease; ECMO, extracorporeal membrane oxygenation.
a 28-day mortality, mortality 28 days after initiation of ECMO.